About ABBV-744 in clinical trials for non-small cell lung cancer (NSCLC)
In Segment C, contributors will obtain ABBV-744 and oral navitoclax. In Phase D, individuals will receive ABBV-744 and ruxolitinib. Members will acquire treatment till disease progression or perhaps the contributors are not able to tolerate the study drugs.Ubiquitin-relevant proteins that control The steadiness of key super enhancer-mediated protei